The phenylalkylamine
emopamil prevents brain damage due to experimental
cerebral ischemia. Stereoselective, high affinity, binding sites for (-)-[3H]
emopamil in guinea pig brain cortex and liver membranes have been proposed to mediate its antiischemic effect. Using [N-methyl-3H]LU49888 as a photoaffinity probe we now provide evidence that the
cation-sensitive
emopamil binding site is localized on a 22-kDa
polypeptide in guinea pig liver, kidney, lung, and adrenal gland. This 22-kDa
polypeptide binds other antiischemic drugs with high affinity and is a nonglycosylated
integral membrane protein of the endoplasmic reticulum. It can be solubilized with
digitonin without changes in its
drug-binding properties. The solubilized binding activity has a sedimentation coefficient of 12.0 +/- 0.4 S and an apparent Stokes radius of 6.0 +/- 0.1 nm. From these data it is concluded that the 22-kDa
polypeptide is associated in a larger oligomeric complex with a molecular mass of at least 84 kDa. [N-methyl-3H]LU49888 also specifically labels a second 27-kDa
polypeptide in the endoplasmic reticulum, which can be distinguished from the 22-kDa
polypeptide by its pharmacological and hydrodynamic properties. The photolabeled 22-kDa
polypeptide was partially purified under denaturating conditions. This will allow the further structural analysis of this putative target for antiischemic drugs.